CEL-SCI to Present Multikine® Data at ESMO 2024 Congress
CEL-SCI Corporation (NYSE American: CVM) announced that it will present new data from its Phase 3 study of Multikine (Leukocyte Interleukin Injection) at the European Society for Medical Oncology (ESMO) 2024 Congress, taking place from September 13-17, 2024, in Barcelona,…
Paragon 28 Unveils New Right-Angle Drill for APEX 3D™ Ankle Replacement System
Paragon 28, Inc. (NYSE: FNA) is excited to introduce a new Right-Angle Drill for its APEX 3D™ Total Ankle Replacement System. This innovative tool is designed to enhance tibia preparation before implanting the APEX 3D™ tibia implant. The Right-Angle Drill…
Cellino Secures $25M Funding from ARPA-H
Cellino Biotech, Inc. announced today that it has been awarded up to $25 million by the Advanced Research Projects Agency for Health (ARPA-H), a division of the U.S. Department of Health and Human Services. The funding will support the development…
Delta-Fly Pharma Begins Phase I/II Study of DFP-10917 with Venetoclax in AML Patients
Following our April 8, 2024, announcement, we’re excited to provide an update on our progress. The U.S. Food and Drug Administration (FDA) approved a Phase I/II clinical trial for DFP-10917 in combination with venetoclax (VEN) for patients with acute myeloid…
UpScriptHealth Expands CGM Access for Diabetes Patients in Partnership with Dexcom
UpScriptHealth, a leading direct-to-patient telehealth company offering new distribution channels for pharmaceutical and medical device brands, announced the expansion of its partnership with Dexcom, the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Following the success…
Catalyst OrthoScience Hits 10,000 TSA Procedures and Secures $20M Funding
Catalyst OrthoScience Inc., a private medical technology company specializing in shoulder arthroplasty—the fastest growing segment in the orthopedics market—has surpassed 10,000 total shoulder arthroplasty (TSA) procedures. The milestone coincides with the successful close of $20 million in equity and venture…
Oisín Biotechnologies Publishes Preclinical Data on Muscle Gene Therapy in Cell
Oisín Biotechnologies, a private biotech firm focused on combating age-related diseases, announced the publication of preclinical data from its follistatin (FST) gene therapy program aimed at reducing muscle loss. The research, titled “Safe and Effective Delivery of DNA and RNA…
Day 2 of 11th Annual World Patient Safety Summit Focuses on Collaboration and Advanced Tech
On the second day of the 11th Annual World Patient Safety, Science & Technology Summit, hosted by the Patient Safety Movement Foundation (PSMF) at UC Irvine, the focus was on the critical role of collaboration in achieving a future free…
BeiGene Showcases TEVIMBRA® Data in Lung and GI Cancers at ESMO 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced it will present new data on TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, from September 13-17, 2024. BeiGene…
JuneBrain Wins MDIC Award; Chooses Compliance Group for Siemens Polarion Implementation
JuneBrain is thrilled to announce that it has received a $300,000 grant from the Medical Device Innovation Consortium’s Advanced Manufacturing Clearing House program. The funding will support the modernization of JuneBrain’s quality management system in collaboration with Compliance Group (CG)…
Doctors Opt for Contrast-Enhanced Ultrasound, Unaware of Favorable Reimbursement
Doctors are increasingly using contrast-enhanced ultrasound (CEUS) for imaging kidney masses in patients with polycystic kidney disease, often bypassing CT scans altogether due to CEUS’s effectiveness. “They go right to CEUS and no longer bother with CT,” said Dr. Richard…
Novel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III
An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…